Acute Respiratory Distress Syndrome Market Predicted to See Upsurge Through 2034, Highlights DelveInsight | Veru, Athersys, Inc, Histocell, BioXcellerator, Altor BioScience, Cartesian Therapeutics, Meridigen Biotech Co., Ltd., Sage Therapeutics, Healios K

DelveInsight's "Acute Respiratory Distress Syndrome Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Acute Respiratory Distress Syndrome, historical and forecasted epidemiology as well as the Acute Respiratory Distress Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the Acute Respiratory Distress Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acute Respiratory Distress Syndrome Market Forecast
https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-ards-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Acute Respiratory Distress Syndrome Market Report:
• The Acute Respiratory Distress Syndrome market size was valued approximately ~USD 1,643 Million in 2023 and is anticipated to grow with a significant CAGR of 3.6 % during the study period (2020-2034)
• In February 2025, Bonus Biogroup (TASE: BONS), a late-stage biotech firm specializing in immunomodulatory and regenerative mesenchymal stromal cell (MSC) therapies, has announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to initiate a Phase III clinical trial in the U.S. The study will assess the safety and effectiveness of MesenCureTM-an allogeneic cell therapy composed of enhanced MSCs derived from adipose tissue-for the treatment of respiratory distress in severely ill, hospitalized patients suffering from COVID-19-related pneumonia. MesenCure is designed to address inflammation and tissue damage.
• In January 2025, InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company developing anti-inflammatory therapies targeting the complement system, has announced that the European Commission (EC) has granted marketing authorization under exceptional circumstances for GOHIBIC® (vilobelimab). This approval covers the treatment of adult patients with SARS-CoV-2-induced acute respiratory distress syndrome (ARDS) who are receiving systemic corticosteroids as part of standard care and require invasive mechanical ventilation (IMV), with or without extracorporeal membrane oxygenation (ECMO). GOHIBIC is the first and only approved therapy in the EU specifically for SARS-CoV-2-related ARDS.
• In November 2024, InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical firm specializing in anti-inflammatory treatments targeting the complement system, announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive recommendation for the marketing authorization of GOHIBIC (vilobelimab). The recommendation supports its use under exceptional circumstances for adult patients with SARS-CoV-2-induced acute respiratory distress syndrome (ARDS) who are receiving systemic corticosteroids and invasive mechanical ventilation (IMV), with or without ECMO. The company anticipates a final decision from the European Commission within 67 days.
• In 2023, Germany had the largest market size for Acute Respiratory Distress Syndrome (ARDS) in Europe, reaching approximately USD 206 million, while Spain recorded the smallest market size with around USD 29 million.
• In 2023, the market size for Acute Respiratory Distress Syndrome (ARDS) in Japan was estimated at approximately USD 46 million, representing 3% of the total market across the 7MM.
• In 2023, there were approximately 591 thousand new cases of Acute Respiratory Distress Syndrome (ARDS) in the United States.
• In 2023, the United States represented the largest share of incident cases of Acute Respiratory Distress Syndrome (ARDS), accounting for approximately 62% of the 7MM. Meanwhile, the EU4 and the UK contributed around 34%, and Japan accounted for about 4% of the total population share.
• In 2023, Germany recorded the highest number of incident cases of Acute Respiratory Distress Syndrome (ARDS) among the EU4 countries, with 181 thousand cases, followed by France with 47 thousand cases. Spain had the lowest number, with 25 thousand cases.
• In 2023, it was estimated that the United States had approximately 177 thousand incident cases of mild severity, 276 thousand cases of moderate severity, and 138 thousand cases of severe severity.
• DelveInsight estimates that in 2023, among the risk factor-associated cases of ARDS in the US, there were approximately 210,560 cases of pneumonia, 175,076 cases of sepsis, 18,169 cases of trauma, 61,157 cases of aspiration, 8,974 cases of pancreatitis, 4,757 cases of COVID-19, 63,242 cases of other types, and about 49,340 cases with unknown causes.
• Key Acute Respiratory Distress Syndrome Companies: Veru, Edesa Biotech/Light Chain Bio, Direct Biologics, Healios/Nobel Pharma, Mesoblast, Chrysalis BioTherapeutics, Athersys, Inc, Histocell, BioXcellerator, Altor BioScience, Cartesian Therapeutics, Meridigen Biotech Co., Ltd., Sage Therapeutics, Healios K.K., Chiesi Farmaceutici, Bayer, Altor BioScience, Faron Pharmaceuticals Ltd, AVM Biotechnology LLC, Amyndas Pharmaceuticals S.A., Kinevant Sciences GmbH, Eli Lilly and Company, Suntory Pharmaceutical, Alexion Pharmaceuticals, Laboratoire français de Fractionnement et de Biotechnologies (LFB), Evgen Pharma, Dimerix Bioscience, Mylan, Vanda Pharmaceuticals, Kiniksa Pharmaceuticals Foresee Pharmaceuticals, Boehringer Ingelheim, Staidson (Beijing) Biopharmaceuticals, Biohaven Pharmaceuticals, Chimerix, Edesa Biotech, and others
• Key Acute Respiratory Distress Syndrome Therapies: Sabizabulin (Veru-111), EB05 (paridiprubart), ExoFlo (DB-001), MultiStem (HLCM051), Remestemcel-L, TP508, Traumakine, BIO-11006, MultiStem, Solnatide, VERU-111, Tradipitant, FP-025, HLCM051(MultiStem), and others
• The Acute Respiratory Distress Syndrome epidemiology based on gender analyze that the percentage of cases of Acute Respiratory Distress Syndrome (ARDS) are equal in both the genders
• The Acute Respiratory Distress Syndrome market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Acute Respiratory Distress Syndrome pipeline products will significantly revolutionize the Acute Respiratory Distress Syndrome market dynamics.

Acute Respiratory Distress Syndrome Overview
Acute Respiratory Distress Syndrome (ARDS) is a severe lung condition that causes widespread inflammation and fluid buildup in the lungs, leading to difficulty breathing. It results from various causes such as pneumonia, trauma, sepsis, aspiration, or COVID-19. ARDS can lead to low oxygen levels in the blood, respiratory failure, and may require mechanical ventilation for the patient to breathe. The condition can progress rapidly and is often life-threatening, particularly in critically ill individuals. Treatment typically focuses on supporting breathing, managing the underlying cause, and preventing complications.

Get a Free sample for the Acute Respiratory Distress Syndrome Market Report:
https://www.delveinsight.com/report-store/acute-respiratory-distress-syndrome-ards-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Acute Respiratory Distress Syndrome Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Acute Respiratory Distress Syndrome Epidemiology Segmentation:
The Acute Respiratory Distress Syndrome market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Acute Respiratory Distress Syndrome
• Prevalent Cases of Acute Respiratory Distress Syndrome by severity
• Gender-specific Prevalence of Acute Respiratory Distress Syndrome
• Diagnosed Cases of Episodic and Chronic Acute Respiratory Distress Syndrome

Download the report to understand which factors are driving Acute Respiratory Distress Syndrome epidemiology trends @ Acute Respiratory Distress Syndrome Epidemiology Forecast
https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-ards-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Acute Respiratory Distress Syndrome Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Acute Respiratory Distress Syndrome market or expected to get launched during the study period. The analysis covers Acute Respiratory Distress Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Acute Respiratory Distress Syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Acute Respiratory Distress Syndrome Therapies and Key Companies
• Sabizabulin (Veru-111): Veru
• EB05 (paridiprubart) (Edesa Biotech/Light Chain Bio)
• ExoFlo (DB-001): Direct Biologics
• MultiStem (HLCM051): Healios/Nobel Pharma
• Remestemcel-L: Mesoblast
• TP508: Chrysalis BioTherapeutics
• Traumakine: Faron Pharmaceuticals
• BIO-11006: BioMarck Pharmaceuticals
• MultiStem: Athersys
• Solnatide: Apeptico Forschung und Entwicklung GmbH

Discover more about therapies set to grab major Acute Respiratory Distress Syndrome market share @ Acute Respiratory Distress Syndrome Treatment Market
https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-ards-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Scope of the Acute Respiratory Distress Syndrome Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Acute Respiratory Distress Syndrome Companies: Veru, Edesa Biotech/Light Chain Bio, Direct Biologics, Healios/Nobel Pharma, Mesoblast, Chrysalis BioTherapeutics, Athersys, Inc, Histocell, BioXcellerator, Altor BioScience, Cartesian Therapeutics, Meridigen Biotech Co., Ltd., Sage Therapeutics, Healios K.K., Chiesi Farmaceutici, Bayer, Altor BioScience, Faron Pharmaceuticals Ltd, AVM Biotechnology LLC, Amyndas Pharmaceuticals S.A., Kinevant Sciences GmbH, Eli Lilly and Company, Suntory Pharmaceutical, Alexion Pharmaceuticals, Laboratoire français de Fractionnement et de Biotechnologies (LFB), Evgen Pharma, Dimerix Bioscience, Mylan, Vanda Pharmaceuticals, Kiniksa Pharmaceuticals Foresee Pharmaceuticals, Boehringer Ingelheim, Staidson (Beijing) Biopharmaceuticals, Biohaven Pharmaceuticals, Chimerix, Edesa Biotech, and others
• Key Acute Respiratory Distress Syndrome Therapies: Sabizabulin (Veru-111), EB05 (paridiprubart), ExoFlo (DB-001), MultiStem (HLCM051), Remestemcel-L, TP508, Traumakine, BIO-11006, MultiStem, Solnatide, VERU-111, Tradipitant, FP-025, HLCM051(MultiStem), and others
• Acute Respiratory Distress Syndrome Therapeutic Assessment: Acute Respiratory Distress Syndrome current marketed and Acute Respiratory Distress Syndrome emerging therapies
• Acute Respiratory Distress Syndrome Market Dynamics: Acute Respiratory Distress Syndrome market drivers and Acute Respiratory Distress Syndrome market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Acute Respiratory Distress Syndrome Unmet Needs, KOL's views, Analyst's views, Acute Respiratory Distress Syndrome Market Access and Reimbursement

To know more about Acute Respiratory Distress Syndrome companies working in the treatment market, visit @ Acute Respiratory Distress Syndrome Clinical Trials and Treatment
https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-ards-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Acute Respiratory Distress Syndrome Market Report Introduction
2. Executive Summary for Acute Respiratory Distress Syndrome
3. SWOT analysis of Acute Respiratory Distress Syndrome
4. Acute Respiratory Distress Syndrome Patient Share (%) Overview at a Glance
5. Acute Respiratory Distress Syndrome Market Overview at a Glance
6. Acute Respiratory Distress Syndrome Disease Background and Overview
7. Acute Respiratory Distress Syndrome Epidemiology and Patient Population
8. Country-Specific Patient Population of Acute Respiratory Distress Syndrome
9. Acute Respiratory Distress Syndrome Current Treatment and Medical Practices
10. Acute Respiratory Distress Syndrome Unmet Needs
11. Acute Respiratory Distress Syndrome Emerging Therapies
12. Acute Respiratory Distress Syndrome Market Outlook
13. Country-Wise Acute Respiratory Distress Syndrome Market Analysis (2020-2034)
14. Acute Respiratory Distress Syndrome Market Access and Reimbursement of Therapies
15. Acute Respiratory Distress Syndrome Market Drivers
16. Acute Respiratory Distress Syndrome Market Barriers
17. Acute Respiratory Distress Syndrome Appendix
18. Acute Respiratory Distress Syndrome Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:

Acute Respiratory Distress Syndrome Pipeline https://www.delveinsight.com/report-store/acute-respiratory-distress-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Acute Respiratory Distress Syndrome Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Acute Respiratory Distress Syndrome market. A detailed picture of the Acute Respiratory Distress Syndrome pipeline landscape is provided, which includes the disease overview and Acute Respiratory Distress Syndrome treatment guidelines.

Acute Respiratory Distress Syndrome Epidemiology https://www.delveinsight.com/report-store/acute-respiratory-distress-syndrome-ards-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Acute Respiratory Distress Syndrome Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Acute Respiratory Distress Syndrome epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports Offered By DelveInsight:
• Healthcare Competitive Benchmarking: https://www.delveinsight.com/consulting/competitive-benchmarking-services
• Tbi Market: https://www.delveinsight.com/report-store/traumatic-brain-injury-market
• Indwelling Catheters Market: https://www.delveinsight.com/report-store/indwelling-catheters-market
• Hyperlipidemia Market: https://www.delveinsight.com/report-store/hyperlipidemia-market
• Inflammatory Bowel Disease Market: https://www.delveinsight.com/report-store/crohns-disease-cd-market
• Post Menopausal Osteoporosis Market: https://www.delveinsight.com/report-store/post-menopausal-osteoporosis-pipeline-insight
• HiPost Menopausal Osteoporosis Market: https://www.delveinsight.com/report-store/post-menopausal-osteoporosis-pipeline-insight

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.